Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 11/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599128 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1803471 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1803672 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1803673 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1803473 | 1.00 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL2599029 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL2598888 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1802872 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL2599009 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C | |
| SCHEMBL1802870 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | claimed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | ADRA2A 81/4885ADRA2B 106/4885ADRA2C 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.